Search Within

Michael David Offin

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (33)
  2. Meeting Abstract (27)
  3. Editorial (2)
  4. Review (1)
Groups
  1. Department of Medicine (63)
  2. Sloan Kettering Institute Postdocs (63)
  3. Solid Tumor Oncology Division (63)
  4. Thoracic Oncology (63)
  5. Weinberg Fellows (63)
  6. GSK Faculty (49)

More Groups

People
  1. Charles Rudin (32)
  2. Marc Ladanyi (30)
  3. Mark Kris (23)
  4. Alexander Drilon (20)
  5. Romel Somwar (20)
  6. Gregory Riely (19)

More People

Years
  1. 2025 (1)
  2. 2024 (8)
  3. 2023 (3)
  4. 2022 (9)
  5. 2021 (13)
  6. 2020 (8)

More Years

Publications
  1. Journal of Thoracic Oncology (14)
  2. Clinical Cancer Research (8)
  3. Journal of Clinical Oncology (6)
  4. International Journal of Radiation Oncology, Biology, Physics (5)
  5. Annals of Oncology (4)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. Elsevier Inc. (21)
  2. American Association for Cancer Research (14)
  3. American Society of Clinical Oncology (10)
  4. Oxford University Press (6)
  5. Biomed Central Ltd (2)
  6. Cell Press (2)

More Publishers

Results (63)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
    Journal Article

    Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Immunophenotype and response to immunotherapy of RET-rearranged lung cancers
    Journal Article

    Offin, M.; Guo, R.; Wu, S. L.; Sabari, J.; Land, J. D.; Ni, A.; Montecalvo, J.; Halpenny, D. F.; Buie, L. W.; Pak, T.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers
    Journal Article

    Vojnic, M.; Kubota, D.; Kurzatkowski, C.; Offin, M.; Suzawa, K.; Benayed, R.; Schoenfeld, A. J.; Plodkowski, A. J.; Poirier, J. T.; Rudin, C. M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez-Vega, F.; Li, B. T.; Drilon, A.; Kris, M. G.; Rudin, C. M.; Schultz, N.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Lu, D.; Kurzatkowski, C.; Vojnic, M.; Smith, R. S.; Sabari, J. K.; Tai, H.; Mattar, M.; Khodos, I.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • RET-rearranged lung cancers: Immunophenotype and response to immunotherapy
    Meeting Abstract

    Sabari, J. K.; Offin, M. D.; Wu, S. L.; Ni, A.; Halpenny, D.; Montecalvo, J.; Liu, D.; Pak, T. K.; Arbour, K. C.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers
    Meeting Abstract

    Offin, M. D.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez Vega, F.; Kris, M. G.; Rudin, C. M.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Somwar, R.; Rekhtman, N.; Benayed, R.; Chang, J. C.; Plodkowski, A.; Lui, A. J. W.; Eng, J.; Rosenblum, M.; Li, B. T.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save